Last reviewed · How we verify
Oral Capsule Mexiletine (IR)
Oral Capsule Mexiletine (IR) is a Class IB antiarrhythmic agent Small molecule drug developed by Lupin Ltd.. It is currently in Phase 3 development for Ventricular arrhythmias, Suppression of premature ventricular contractions, Long QT syndrome (certain forms).
Mexiletine is a class IB antiarrhythmic agent that blocks cardiac sodium channels to suppress abnormal electrical activity and restore normal heart rhythm.
Mexiletine is a class IB antiarrhythmic agent that blocks cardiac sodium channels to suppress abnormal electrical activity and restore normal heart rhythm. Used for Ventricular arrhythmias, Suppression of premature ventricular contractions, Long QT syndrome (certain forms).
At a glance
| Generic name | Oral Capsule Mexiletine (IR) |
|---|---|
| Sponsor | Lupin Ltd. |
| Drug class | Class IB antiarrhythmic agent |
| Target | Cardiac voltage-gated sodium channel (Nav1.5) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Mexiletine works by inhibiting fast inward sodium currents in cardiac tissue, which decreases the rate of depolarization and slows conduction velocity. This action suppresses ectopic activity and abnormal automaticity in the heart, making it effective for treating various cardiac arrhythmias. The drug has a rapid onset and short half-life, allowing for flexible dosing.
Approved indications
- Ventricular arrhythmias
- Suppression of premature ventricular contractions
- Long QT syndrome (certain forms)
Common side effects
- Tremor
- Dizziness
- Nausea
- Ataxia
- Blurred vision
- Proarrhythmic effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Capsule Mexiletine (IR) CI brief — competitive landscape report
- Oral Capsule Mexiletine (IR) updates RSS · CI watch RSS
- Lupin Ltd. portfolio CI
Frequently asked questions about Oral Capsule Mexiletine (IR)
What is Oral Capsule Mexiletine (IR)?
How does Oral Capsule Mexiletine (IR) work?
What is Oral Capsule Mexiletine (IR) used for?
Who makes Oral Capsule Mexiletine (IR)?
What drug class is Oral Capsule Mexiletine (IR) in?
What development phase is Oral Capsule Mexiletine (IR) in?
What are the side effects of Oral Capsule Mexiletine (IR)?
What does Oral Capsule Mexiletine (IR) target?
Related
- Drug class: All Class IB antiarrhythmic agent drugs
- Target: All drugs targeting Cardiac voltage-gated sodium channel (Nav1.5)
- Manufacturer: Lupin Ltd. — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Ventricular arrhythmias
- Indication: Drugs for Suppression of premature ventricular contractions
- Indication: Drugs for Long QT syndrome (certain forms)
- Compare: Oral Capsule Mexiletine (IR) vs similar drugs
- Pricing: Oral Capsule Mexiletine (IR) cost, discount & access